How long does it take for resistance to capmatinib to develop?

Capmatinib is a targeted therapy drug specifically targeted for patients with non-small cell lung cancer (NSCLC) who carry MET gene mutations or MET exon 14 skipping mutations. MET exon 14 skipping mutation is an important driver mutation in non-small cell lung cancer. Capmatinib can effectively inhibit the tumor growth signal caused by this mutation, thereby controlling tumor expansion. Although capmatinib has shown good efficacy in treating such patients, like other targeted drugs, the use of capmatinib may also face resistance problems.

Generally speaking, resistance to capmatinib usually occurs between a few months and a year after using the drug. The specific time varies depending on the individual differences of the patient, the characteristics of the disease, and the response to treatment. In clinical studies, most patients develop resistance to capmatinib within 6 to 12 months. However, this time window is not fixed. Some patients may experience resistance in a shorter period of time, while others may respond to treatment over a longer period of time, with resistance emerging relatively late.

The emergence of drug resistance is related to multiple factors. First, tumor cells escape the inhibitory effect of capmatinib through various mechanisms, resulting in the gradual weakening of the drug's efficacy. Research shows that different types of MET gene mutations may affect how quickly drug resistance emerges. For example, patients with MET exon 14 skipping mutations may develop resistance earlier after treatment, whereas patients with other types of MET mutations may maintain sensitivity to treatment longer.

Secondly, tumor cells may acquire new drug resistance mechanisms through gene mutations or epigenetic changes. For example, some patients' tumor cells may develop new mutations during treatment with capmatinib, making the inhibition of the MET pathway ineffective. In addition, tumor cells may evade the inhibitory effects of drugs by activating other oncogenic pathways (such as EGFR, HER2, or PI3K/AKT pathways), which may also accelerate the development of drug resistance.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib